Other languages Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
21.17 ^USD	-1.67%		-1.53%	-30.57%

Apr. 15	Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	CI
Mar. 25	Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	Apr. 15
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 25
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 22
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	Mar. 18
Intellia Therapeutics Q4 Loss Widens	Feb. 22
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis	Feb. 15
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	Feb. 15
Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study	Feb. 01
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine	Jan. 31
Intellia Therapeutics Insider Sold Shares Worth $566,310, According to a Recent SEC Filing	Jan. 05
Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees	Dec. 06
Intellia Therapeutics Files Mixed Shelf	Nov. 27
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy	Nov. 14
Intellia Therapeutics Shares Fall After Net Loss Narrows, but Revenue Falls in Q3	Nov. 09
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Intellia Therapeutics Says Its Protein Disorder Treatment Candidate Showed Consistent Reduction of Plasma Protein in Phase 1 Trial	Nov. 02
Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting	Nov. 02
Intellia Therapeutics Says Application for Investigational Transthyretin Amyloidosis Treatment Cleared by FDA	23-10-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Other languages

Filters